Search
6 articles for “neuropsychiatric”
-
Exploring the Role of MAPK3 in Major Depressive Disorder: Molecular Docking, Dynamics, and Binding Free Energy Analysis of Natural Compounds as Alternatives to Conventional Drugs
Abstract: Major Depressive Disorder (MDD) is a prevalent neuropsychiatric disorder with limited treatment efficacy and significant side effects associated with conventional antidepressants. Recent studies have highlighted the role of mitogen-activated protein kinase 3 (MAPK3) in the mechanisms underlying MDD, positioning it as a potential target for the development of novel therapeutic drugs. In this study, we employed various computational approaches to explore natural compounds as viable alternatives to synthetic antidepressants. Researchers …
Published in International Journal of Bioinformatics and Computational Biology · Vol. 3, Issue 2, 2025 · pp. 53–68 Read article
-
The Renaissance and Resilience of CB1 Reverse Agonists: From Central Liabilities to Peripheral Promise
Abstract: Building upon these foundational insights, current research has increasingly focused on refining the pharmacological profile of CB1 reverse agonists to maximize therapeutic benefit while minimizing central adverse effects. The adverse neuropsychiatric outcomes associated with first-generation agents such as Rimonabant including anxiety, depression, and suicidal ideation highlighted the critical role of central CB1 receptors in mood regulation. Consequently, drug development strategies have shifted toward peripherally restricted CB1 reverse agonists that exhibit …
Published in International Journal of Cheminformatics · Vol. 4, Issue 1, 2026 · pp. 30–35 Read article
-
Application of Drug Delivery using Nano- technology to Cure Mental Disorders (Schizophrenia)
Abstract: Nanotechnology involves the manipulation of the count at an atomic scale to create novel systems, materials, and devices. This groundbreaking era holds substantial potential for scientific development across various domain names, which includes manufacturing, patron items, electricity, substances, and remedies. In current times, the sphere of prescribed drugs has witnessed a brilliant surge in the usage of nanotechnology for the improvement of revolutionary medications. Schizophrenia, a neuropsychiatric disorder affecting the …
Published in Research and Reviews : A Journal of Life Sciences · Vol. 14, Issue 1, 2024 · pp. 51–65 Read article
-
Computational Investigation of Phytochemicals Targeting AKT1 for Major Depressive Disorder: A Molecular Docking and ADMET Study
Abstract: Major depressive disorder (MDD) is a prevalent neuropsychiatric condition affecting approximately 280 million individuals worldwide, with women exhibiting a 50% higher likelihood of diagnosis than men. Despite significant advancements in treatment, MDD remains a chronic and relapsing disorder, necessitating the exploration of novel therapeutic interventions. This study focuses on the AKT1 gene, a key player in neuropsychiatric disorders, and investigates its interactions with natural phytochemicals as potential alternatives to conventional …
Published in Research and Reviews : Journal of Computational Biology · Vol. 14, Issue 2, 2025 Read article
-
An Extensive Analysis of Computer-Aided Drug Design for Novel Psychotropic and Neurological Substances
Abstract: A comprehensive review of the use of computer-aided drug design (CADD) in the creation of innovative neurologic and neuropsychiatric medications is given in this article. It discusses the challenges in traditional drug discovery approaches and highlights the role of computational methods in accelerating the identification and optimization of drug candidates targeting psychiatric and neurological disorders. The method of finding new drugs has been completely transformed by Computer-Aided Drug Design (CADD), …
Published in International Journal of Brain Sciences · Vol. 1, Issue 2, 2024 · pp. 19–27 Read article
-
CB₁ Reverse Agonists: A Cheminformatic and Patent Landscape Study
Abstract: The endocannabinoid system plays a crucial role in numerous physiological functions, making cannabinoid receptor 1 (CB1) an attractive target for therapeutic development. This review provides a systematic analysis of patent filings from 2019 to 2023 that focus on small-molecule CB1 reverse agonists. It begins with an overview of the endocannabinoid system, highlighting CB1’s involvement in energy balance, pain regulation, and neuroinflammatory processes The main section of the review examines fifteen …
Published in International Journal of Cheminformatics · Vol. 3, Issue 2, 2025 · pp. 33–36 Read article